FeaturedNeuroscience·January 20, 2025·6 min readGLP-1 Drugs Offer Brain Benefits but May Pose Other Health RisksA study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.Read More
FeaturedNeurologyNeuroscience·October 24, 2024·4 min readOzempic Shows Potential in Lowering Alzheimer’s RiskNew research suggests that semaglutide, a popular diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes. The study compared semaglutide to seven other anti-diabetic drugs and found it was linked to a significantly lower risk of developing Alzheimer’s.Read More
FeaturedNeurologyNeuroscience·October 6, 2024·5 min readStudy Finds Wegovy Reduces COVID-19 Death Risk by One-ThirdA new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%. The study followed more than 17,000 participants with heart disease and obesity, showing that Wegovy decreased the likelihood of death from cardiovascular disease by 15% and other causes by 23%.Read More
FeaturedNeurologyNeuroscience·July 12, 2024·5 min readOzempic Reduces Dementia Risk, Curbs Nicotine CravingsA new study finds that semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and may reduce cognitive problems and nicotine dependence. The analysis, using over 100 million patient records, revealed no increased risk of neurological or psychiatric conditions compared to other antidiabetic medications. These findings suggest semaglutide's benefits may extend beyond diabetes management. Further research is needed to confirm these potential benefits.Read More
FeaturedNeurologyNeuroscience·June 21, 2024·4 min readOzempic May Reduce Alzheimer’s RiskGLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.Read More
FeaturedNeurosciencePsychology·June 3, 2024·3 min readOzempic May Reduce Alcohol Abuse RiskDiabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.Read More
